Perrigo, which sought FDA approval for an over-the-counter version last summer after the Supreme Court's ruling that overturned Roe v. Wade, expects a final decision by the end of summer in the U.S.
Under mounting pressure, Novo Nordisk plans to cut list prices for insulin products by up to 75%, now the latest drugmaker to take such a step following a California lawsuit accusing drugmakers of driving up costs.